Sancilio Pharmaceuticals Company, which markets, licenses and develops products based on its lipid drug delivery technology, withdrew its plans for an initial public offering on Friday. It originally filed in August 2015 with a proposed deal size of $86 million.
The Riviera Beach, FL-based company was founded in 2006 and booked $25 million in sales for the 12 months ended December 31, 2015. It had planned to list on the Nasdaq under the symbol SPCI. UBS Investment Bank, Piper Jaffray, JMP Securities and FBR Capital Markets were set to be the joint bookrunners on the deal.
The article Sancilio Pharmaceuticals, a lipid focused biotech, withdraws $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
